Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research report released on Tuesday morning, Benzinga reports. Wedbush currently has a $11.00 price target on the stock.

Several other analysts have also recently weighed in on the company. HC Wainwright reissued a buy rating and set a $17.50 price target on shares of Vor Biopharma in a report on Thursday, March 21st. JMP Securities reissued a market outperform rating and set a $12.00 price target on shares of Vor Biopharma in a report on Friday, March 22nd. Oppenheimer reissued an outperform rating and set a $15.00 price target (down from $17.00) on shares of Vor Biopharma in a report on Thursday, March 21st. Finally, Stifel Nicolaus dropped their price target on Vor Biopharma from $15.00 to $12.00 and set a buy rating for the company in a report on Thursday, March 21st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vor Biopharma presently has an average rating of Buy and an average target price of $13.50.

Vor Biopharma Stock Up 3.3 %

VOR opened at $1.88 on Tuesday. Vor Biopharma has a 12-month low of $1.62 and a 12-month high of $5.70. The business has a 50 day moving average of $2.04 and a 200-day moving average of $2.11.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.10. Analysts forecast that Vor Biopharma will post -1.34 EPS for the current year.

Hedge Funds Weigh In On Vor Biopharma

A hedge fund recently raised its stake in Vor Biopharma stock. Exchange Traded Concepts LLC raised its stake in Vor Biopharma Inc. (NYSE:VOR) by 34.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,170 shares of the company’s stock after acquiring an additional 15,258 shares during the period. Exchange Traded Concepts LLC owned approximately 0.09% of Vor Biopharma worth $135,000 at the end of the most recent quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.